Inhibitor Therapeutics, Inc.
Inhibitor Therapeutics, Inc. (INTI) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
inti · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 5 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Inhibitor Therapeutics, Inc.You INTI | $15M | N/A | — | — |
 BetterLife Pharma Inc. BETRF | $7M | N/A | — | -$0.01 |
 Chimeric Therapeutics Limited CHMMF | $4M | N/A | — | -$0.77 |
 Curative Biotechnology, Inc. CUBT | $11M | N/A | — | -$0.00 |
 Devonian Health Group Inc. DVHGF | $30M | N/A | — | -$1.76 |
 LianBio LIANY | $12M | 2.11x | — | $0.05 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Inhibitor Therapeutics, Inc. (INTI) measures how much investors pay for each dollar of the company's trailing earnings. INTI's current PE ratio of N/A is calculated by dividing its stock price of $0.08 by its TTM earnings per share of —.
Frequently asked questions
INTI pe ratio · 6 questionsINTI's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.08 and TTM EPS of —. Data sourced from Financial Modeling Prep via INTI's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Inhibitor Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09